The Invisible Architect — How Data
Shapes Our Environment and Choices
Modern Healthcare
Genomic data & precision medicine:
tailoring drug treatment based on a patient's DNA profile
Consider a woman with breast cancer. Her oncologist prescribes her the standard
chemotherapy. It fails as her BRCA1 was mutated which her doctor didn’t know and
couldn’t have known without her genomic data. BRCA1 is a tumor suppressing gene and
those with a broken BRCA1 get attacked by PARP which is a cancer cell which only relies on
this mutated BRCA1. Without this information not only are the drugs administered to her
are rendered ineffective, they could be fatal. Data promises to change this by tailoring
drug treatment based on a patient's genome profile.
The standard practice in the medical industry is to design the medicine for the average
patient. Today, nearly half of all prescribed drugs fail to work in the patients who take
them. A central reason is pharmacogenomics which is the way genetic variants alter how
the body absorbs, distributes and metabolises the medicine. Enzymes in the liver,
particularly the CYP450 family, metabolise 70-80% drugs. Genetic variants make one
person a poor metaboliser, causing a standard dose to accumulate to toxic levels, and
another a rapid metaboliser, causing it to clear before it works. The barrier to this was
performing genome sequencing which costed $3 billion and 10 years time in 2003 and today
just costs $200.
Precision medicine works either by reading the whole genome sequence or targeted
sequence and cross reference them against massive biobanks to identify mutations.
Machine Learning algorithms trained on this data can help speed up the process and
identify which mutations correlate with specific drug responses, toxicities, and survival
outcomes. The output is not a diagnosis but an evidence based probability: a ranked list of
treatments that are most likely to work for the patient's biology. Companies like Tempus
AI have built clinical platforms that deliver exactly this to the oncologists. This way they
gain a partner who surfaces drug mutation matches no human could do, across thousands of
patients. Beneficiaries see immediate and tangible differences.
While exciting and promising, this system is far from perfect. In 2025, 23andMe filed for
bankruptcy, leaving fifteen million people's genomic data with no clear legal protection
meaning anyone can acquire this. Genomic data is not a password and cannot be reset.
Another issue with genomic data is that over 80% of research being done is on European
ancestry meaning the predictive models are weakest for those who already receive
inadequate and inequitable care.
The woman with the BRCA1 is the central figure of the story. In one version, genomic data
catches her cancer early, matches her to the right drug, and she survives. In another, her
data is sold, her insurer adjusts her premium, and the model trained without her ancestry
returns an uncertain result. Precision medicine's promise is real but so is its responsibility.
The question is not whether it will redesign medicine, but whether those who build with it
will design for everyone.